Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 12/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | BLK | P51451 | 1/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29632299 | 0.91 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL24936315 | 0.91 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL30522663 | 0.89 | CHEK1 (0.82) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL24935500 | 0.89 | CHEK1 (0.82) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL24936223 | 0.85 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL29632305 | 0.85 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL24936279 | 0.85 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL24936228 | 0.84 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL24936317 | 0.84 | CHEK1 (0.72) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| SCHEMBL25284772 | 0.81 | CHEK1 (0.68) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | claimed |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-09 | — | — | US | claimed |
| EP-4534100-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-09 | — | — | EP | claimed |
| CN-119403571-A | Therapeutic agent for cancer having therapeutic resistance to immune checkpoint inhibitor | 住友制药株式会社 | 2025-02-07 | — | — | CN | claimed |
| WO-2023229032-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | 住友ファーマ株式会社 | 2023-11-30 | — | — | WO | claimed |
| EP-4253377-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-04 | — | — | EP | claimed |
| CN-116546974-A | 5-heteroaryl-1H-pyrazol-3-amine derivatives | 住友制药株式会社 | 2023-08-04 | — | — | CN | claimed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | claimed |
| WO-2022114189-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | 住友ファーマ株式会社 | 2022-06-02 | — | — | WO | claimed |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4534100-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-09 | — | — | EP | disclosed |
| CN-119403571-A | Therapeutic agent for cancer having therapeutic resistance to immune checkpoint inhibitor | 住友制药株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220273649-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-01 | — | — | US | disclosed |
| WO-2022114189-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | 住友ファーマ株式会社 | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885 |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885 |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, WEE1 | CHEK1 1/4885KCNH2 1341/4885NUAK1 268/4885 |
| US-20220273649-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885 |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | CHEK1 1/4885KCNH2 2700/4885NUAK1 124/4885 |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | CHEK1, CHEK2, PDCD1 | CHEK1 1/4885KCNH2 2395/4885NUAK1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.